CO5540294A2 - Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienen - Google Patents
Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienenInfo
- Publication number
- CO5540294A2 CO5540294A2 CO03104435A CO03104435A CO5540294A2 CO 5540294 A2 CO5540294 A2 CO 5540294A2 CO 03104435 A CO03104435 A CO 03104435A CO 03104435 A CO03104435 A CO 03104435A CO 5540294 A2 CO5540294 A2 CO 5540294A2
- Authority
- CO
- Colombia
- Prior art keywords
- combination
- cyclphosphamide
- carmustine
- compositions containing
- rapamycin derivative
- Prior art date
Links
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 title 1
- 229960005243 carmustine Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 239000002295 alkylating antineoplastic agent Substances 0.000 abstract 3
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29519001P | 2001-06-01 | 2001-06-01 | |
| US29523601P | 2001-06-01 | 2001-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5540294A2 true CO5540294A2 (es) | 2005-07-29 |
Family
ID=26968972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO03104435A CO5540294A2 (es) | 2001-06-01 | 2003-11-26 | Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienen |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1392286A2 (https=) |
| JP (1) | JP2004532883A (https=) |
| KR (1) | KR100875611B1 (https=) |
| CN (1) | CN100496485C (https=) |
| AU (2) | AU2002259309B2 (https=) |
| BR (1) | BR0210101A (https=) |
| CA (1) | CA2447732A1 (https=) |
| CO (1) | CO5540294A2 (https=) |
| EA (1) | EA007530B1 (https=) |
| HU (1) | HUP0400006A2 (https=) |
| IL (1) | IL158800A0 (https=) |
| MX (1) | MXPA03010907A (https=) |
| NO (1) | NO20035317L (https=) |
| NZ (1) | NZ529877A (https=) |
| PL (1) | PL367267A1 (https=) |
| SG (1) | SG153647A1 (https=) |
| WO (1) | WO2002098416A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX368013B (es) | 2001-02-19 | 2019-09-13 | Novartis Ag | Tratamiento de cáncer. |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| AR046194A1 (es) | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
| KR101313702B1 (ko) | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
| EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| NO20220050A1 (no) * | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendokrin tumorbehandling |
| GB0523658D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| US20090023768A1 (en) * | 2006-02-24 | 2009-01-22 | Novartis Ag | Rapamycin derivatives for treating neuroblastoma |
| US20090098137A1 (en) * | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| EP2131821B1 (en) * | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| BRPI0914790A2 (pt) | 2008-06-17 | 2015-10-20 | Wyeth Llc | uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| DK3000467T3 (da) | 2009-04-06 | 2023-03-27 | Wyeth Llc | Behandling med neratinib mod brystkræft |
| CN103721189A (zh) * | 2013-12-27 | 2014-04-16 | 刘玉含 | 一种脑膜瘤护理药物及其制备方法 |
| CN105168204A (zh) * | 2015-09-06 | 2015-12-23 | 江志鑫 | 一种含有丝裂霉素的抗结肠癌药物组合物 |
| CN119732959A (zh) * | 2024-12-31 | 2025-04-01 | 吉林大学 | 具有mTOR抑制能力的制剂在制备抗肿瘤联合用药物组合物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| DK0525960T3 (da) * | 1991-06-18 | 1996-04-15 | American Home Prod | Anvendelse af rapamycin til behandling af T-celle leukæmi/lymfon |
| TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| MX368013B (es) * | 2001-02-19 | 2019-09-13 | Novartis Ag | Tratamiento de cáncer. |
-
2002
- 2002-05-29 PL PL02367267A patent/PL367267A1/xx not_active Application Discontinuation
- 2002-05-29 AU AU2002259309A patent/AU2002259309B2/en not_active Ceased
- 2002-05-29 CA CA002447732A patent/CA2447732A1/en not_active Abandoned
- 2002-05-29 KR KR1020037015721A patent/KR100875611B1/ko not_active Expired - Fee Related
- 2002-05-29 JP JP2003501455A patent/JP2004532883A/ja not_active Withdrawn
- 2002-05-29 WO PCT/US2002/016737 patent/WO2002098416A2/en not_active Ceased
- 2002-05-29 SG SG200507698-9A patent/SG153647A1/en unknown
- 2002-05-29 IL IL15880002A patent/IL158800A0/xx unknown
- 2002-05-29 NZ NZ529877A patent/NZ529877A/en unknown
- 2002-05-29 EA EA200301319A patent/EA007530B1/ru not_active IP Right Cessation
- 2002-05-29 BR BR0210101-7A patent/BR0210101A/pt not_active Application Discontinuation
- 2002-05-29 CN CNB02811048XA patent/CN100496485C/zh not_active Expired - Fee Related
- 2002-05-29 HU HU0400006A patent/HUP0400006A2/hu unknown
- 2002-05-29 EP EP02729310A patent/EP1392286A2/en not_active Ceased
- 2002-05-29 MX MXPA03010907A patent/MXPA03010907A/es not_active Application Discontinuation
-
2003
- 2003-11-26 CO CO03104435A patent/CO5540294A2/es not_active Application Discontinuation
- 2003-11-28 NO NO20035317A patent/NO20035317L/no not_active Application Discontinuation
-
2008
- 2008-06-18 AU AU2008202690A patent/AU2008202690A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040025923A (ko) | 2004-03-26 |
| EP1392286A2 (en) | 2004-03-03 |
| CN1646120A (zh) | 2005-07-27 |
| JP2004532883A (ja) | 2004-10-28 |
| NO20035317D0 (no) | 2003-11-28 |
| CN100496485C (zh) | 2009-06-10 |
| WO2002098416A2 (en) | 2002-12-12 |
| NZ529877A (en) | 2006-08-31 |
| EA200301319A1 (ru) | 2004-04-29 |
| HUP0400006A2 (hu) | 2004-04-28 |
| NO20035317L (no) | 2003-12-22 |
| CA2447732A1 (en) | 2002-12-12 |
| WO2002098416A3 (en) | 2003-03-13 |
| EA007530B1 (ru) | 2006-10-27 |
| PL367267A1 (en) | 2005-02-21 |
| SG153647A1 (en) | 2009-07-29 |
| AU2008202690A1 (en) | 2008-07-10 |
| KR100875611B1 (ko) | 2008-12-24 |
| MXPA03010907A (es) | 2004-02-17 |
| BR0210101A (pt) | 2004-06-08 |
| IL158800A0 (en) | 2004-05-12 |
| AU2002259309B2 (en) | 2008-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5540294A2 (es) | Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienen | |
| ATE293995T1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
| BR0207872A (pt) | Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração | |
| BR0215184A (pt) | composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| HRP20020158B1 (en) | Action of synergistic combination | |
| NO20032233L (no) | Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer | |
| UY26372A1 (es) | "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen " | |
| AR035500A1 (es) | Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina. | |
| BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| ES2157881T3 (es) | Metanosulfonato de paroxetina. | |
| BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
| CO4970835A1 (es) | Inhibicion de la oxidacion de lipoproteinas | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| DK1121127T3 (da) | Orale farmaceutiske sammensætninger, som indeholder buprenorphin | |
| BRPI0415053A (pt) | inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo | |
| ATE357928T1 (de) | Pharmazeutische zusammensetzung für thrombinpeptidderivaten | |
| PT1210119E (pt) | Composicoes farmaceuticas para administracao oral e topica | |
| ES2189252T3 (es) | Composiciones analgesicas que comprenden un antagonista de la colecistoquinina y un opioide. | |
| HRP20070476T3 (en) | Treatment of dependence withdrawal | |
| EP1254668A3 (en) | Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression | |
| AR032642A1 (es) | Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral. | |
| BRPI0412364A (pt) | composição farmacêutica sólida, compreendendo amisulpride | |
| ES2150404T3 (es) | Composiciones farmaceuticas de tizoxanida y nitozoxanida. | |
| UY26171A1 (es) | Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted | ||
| FD | Application lapsed |